Latest Insider Transactions at Oramed Pharmaceuticals Inc. (ORMP)
This section provides a real-time view of insider transactions for Oramed Pharmaceuticals Inc. (ORMP). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ORAMED PHARMACEUTICALS INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ORAMED PHARMACEUTICALS INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 17
2024
|
Yehuda Reznick Director |
BUY
Grant, award, or other acquisition
|
Direct |
29,800
+50.0%
|
-
|
|
Jan 30
2024
|
Daniel Aghion Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+8.81%
|
-
|
|
Jan 04
2024
|
Joshua Hexter COO & CBO |
BUY
Grant, award, or other acquisition
|
Direct |
180,500
+27.25%
|
-
|
|
Jan 04
2024
|
Nadav Kidron President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
329,000
+15.59%
|
-
|
|
Jan 04
2024
|
Miriam Kidron Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
295,500
+27.9%
|
-
|
|
Jan 04
2024
|
Arie Mayer Director |
BUY
Grant, award, or other acquisition
|
Direct |
39,325
+17.26%
|
-
|
|
Jan 04
2024
|
Yadin Rozov Director |
BUY
Grant, award, or other acquisition
|
Direct |
38,820
+11.19%
|
-
|
|
Jan 04
2024
|
Leonard Sank Director |
BUY
Grant, award, or other acquisition
|
Direct |
39,325
+16.98%
|
-
|
|
Jan 04
2024
|
David Silberman Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
136,500
+27.14%
|
-
|
|
Jan 04
2024
|
Benjamin Shapiro Director |
BUY
Grant, award, or other acquisition
|
Direct |
35,070
+22.97%
|
-
|
|
Jan 04
2024
|
Daniel Aghion Director |
BUY
Grant, award, or other acquisition
|
Direct |
35,070
+31.32%
|
-
|
|
May 26
2023
|
David Silberman Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,500
+9.63%
|
-
|
|
May 26
2023
|
Joshua Hexter COO & CBO |
BUY
Grant, award, or other acquisition
|
Direct |
27,000
+8.22%
|
-
|
|
May 26
2023
|
Netanel Derovan Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,500
+12.06%
|
-
|
|
May 26
2023
|
Miriam Kidron Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
53,500
+10.26%
|
-
|
|
May 26
2023
|
Nadav Kidron President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
120,000
+7.63%
|
-
|
|
May 01
2023
|
Benjamin Shapiro Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+50.0%
|
-
|
|
Apr 17
2023
|
Arie Mayer Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+34.56%
|
-
|
|
Apr 17
2023
|
David Silberman Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
97,500
+32.18%
|
-
|
|
Apr 17
2023
|
Miriam Kidron Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
213,000
+33.94%
|
-
|
|
Apr 17
2023
|
Yadin Rozov Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+20.48%
|
-
|
|
Apr 17
2023
|
Nadav Kidron President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
279,000
+17.32%
|
-
|
|
Apr 17
2023
|
Joshua Hexter COO & CBO |
BUY
Grant, award, or other acquisition
|
Direct |
108,000
+28.25%
|
-
|
|
Apr 17
2023
|
Netanel Derovan Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
81,000
+38.57%
|
-
|
|
Apr 17
2023
|
Leonard Sank Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+33.82%
|
-
|
|
Apr 04
2023
|
Arie Mayer Director |
BUY
Open market or private purchase
|
Direct |
3,800
+12.41%
|
$7,600
$2.21 P/Share
|
|
Apr 03
2023
|
Arie Mayer Director |
BUY
Open market or private purchase
|
Direct |
5,009
+17.88%
|
$10,018
$2.22 P/Share
|
|
Mar 16
2023
|
Nadav Kidron President and CEO |
BUY
Open market or private purchase
|
Indirect |
26,000
+17.11%
|
$52,000
$2.04 P/Share
|
|
Mar 14
2023
|
Nadav Kidron President and CEO |
BUY
Open market or private purchase
|
Indirect |
100,000
+50.0%
|
$200,000
$2.01 P/Share
|
|
Mar 14
2023
|
Miriam Kidron Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
100,000
-33.15%
|
$200,000
$2.01 P/Share
|
|
Mar 14
2023
|
Yadin Rozov Director |
BUY
Open market or private purchase
|
Direct |
50,000
+36.63%
|
$100,000
$2.05 P/Share
|
|
Mar 13
2023
|
Yadin Rozov Director |
BUY
Open market or private purchase
|
Direct |
20,000
+35.4%
|
$20,000
$1.96 P/Share
|
|
Jan 03
2023
|
Michael Rabinowitz Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
13,325
-4.82%
|
$159,900
$12.75 P/Share
|
|
Oct 27
2022
|
Nadav Kidron President and CEO |
SELL
Bona fide gift
|
Direct |
25,000
-2.32%
|
-
|
|
Aug 08
2022
|
Leonard Sank Director |
SELL
Payment of exercise price or tax liability
|
Direct |
9,304
-24.48%
|
$74,432
$8.77 P/Share
|
|
Aug 08
2022
|
Leonard Sank Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+34.48%
|
$80,000
$4.08 P/Share
|
|
Aug 01
2022
|
Nadav Kidron President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
12,631
-1.16%
|
$101,048
$8.36 P/Share
|
|
Jul 28
2022
|
Yadin Rozov Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+42.11%
|
-
|
|
Jul 28
2022
|
Leonard Sank Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+40.0%
|
-
|
|
Jul 28
2022
|
David Silberman Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
39,000
+26.53%
|
-
|
|
Jul 28
2022
|
Michael Rabinowitz Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+17.7%
|
-
|
|
Jul 28
2022
|
Arie Mayer Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+40.0%
|
-
|
|
Jul 28
2022
|
Miriam Kidron Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
118,000
+17.65%
|
-
|
|
Jul 28
2022
|
Nadav Kidron President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
160,000
+6.88%
|
-
|
|
Jul 28
2022
|
Joshua Hexter COO & CBO |
BUY
Grant, award, or other acquisition
|
Direct |
42,000
+20.16%
|
-
|
|
Jul 28
2022
|
Netanel Derovan Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+38.46%
|
-
|
|
May 02
2022
|
Yadin Rozov Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+50.0%
|
-
|
|
Mar 21
2022
|
Kevin Rakin Director |
SELL
Open market or private sale
|
Direct |
10,000
-17.65%
|
$90,000
$9.41 P/Share
|
|
Feb 17
2022
|
Kevin Rakin Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3,010
-5.04%
|
$30,100
$10.63 P/Share
|
|
Feb 17
2022
|
Kevin Rakin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,667
+10.05%
|
$26,668
$4.8 P/Share
|